Begin main content

Search

We found 53 result(s)

Dosing and Timing of Immuno-Oncology Drugs

Last Updated: November 21, 2019
Result type: Reports
Product Line: Optimal Use, Technology Review

Immuno-oncology (IO) drugs (also called immune checkpoint inhibitors or immunotherapy drugs) have transformed the field of cancer. These drugs have elicited unprecedented therapeutic responses, allowing significant regression and sometimes resolution of several cancer types. Dosing of IO therapies investigated in clinical trials is inconsistent ...

  • Project Number: HO0008-000

Triple csDMARDs for Rheumatoid Arthritis

Last Updated: October 9, 2019
Result type: Reports
Product Line: Optimal Use

The project OP0543 Triple csDMARDs for Rheumatoid Arthritis will not be conducted as proposed due to changes in the needs of the jurisdictional customer. As a result, the objectives and needs are currently being reassessed and a revised project may be introduced in the near future.

  • Project Number: OP0543-000
  • Project Status: Cancelled

Canadian Medical Imaging Inventory, 2020

Last Updated: October 8, 2019
Result type: Reports
Product Line: Optimal Use

The Canadian Medical Imaging Inventory collect information on six imaging modalities using a Web-based survey that is supplemented with information from data validators, expert reviewers, and literature searches. The imaging modalities include: Computed tomography (CT) Magnetic resonance imaging (MRI) Single-photon emission computed tomogra...

  • Project Number: OP0546-0000

Axicabtagene Ciloleucel for Adults With Relapsed or Refractory Large B-cell Lymphoma

Last Updated: August 15, 2019
Result type: Reports
Product Line: Optimal Use

Axicabtagene ciloleucel is a chimeric antigen receptor T-cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. This includes diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and subtypes of DLBCL (e.g., primary mediastinal large B-cell lymphoma and DLBCL arising from follicular lymp...

  • Project Number: CT0002-000

Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: A Health Technology Assessment

Last Updated: July 22, 2019
Result type: Reports
Product Line: Optimal Use
Research Type: Device

Major depressive disorder (MDD) is the occurrence of one or more major depressive episodes that last at least two weeks. Anxiety disorders include a range of conditions, including generalized anxiety disorder, panic disorder, and social anxiety disorder. MDD and anxiety disorders may be treated with pharmacological and/or psychological intervent...

  • Project Number: OP0534-000

HPV Testing for Primary Cervical Cancer Screening

Last Updated: July 8, 2019
Result type: Reports
Product Line: Optimal Use

Worldwide, cervical cancer is one of the most frequently diagnosed cancers; however, the incidence of cervical cancer has been decreasing in the past three decades, largely due to routine screening with cytology. HPV is the major risk factor for the development of cervical cancer, with 99% of cervical cancer being associated with HPV. It is one ...

  • Project Number: OP0530-000

Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: Clinical and Economic Impact of Standard Versus Extended Duration

Last Updated: April 4, 2019
Result type: Reports
Product Line: Optimal Use

This project evaluated the clinical and economic effectiveness of extending dual antiplatelet therapy, or DAPT (i.e., a combination of ASA and a P2Y12 inhibitor), following percutaneous coronary intervention (PCI). This project aimed to answer the following policy questions: Policy Question 1: Should P2Y12 inhibitors (i.e., clopidogrel, prasugr...

  • Project Number: OP0533-000

Optimal Use of Minimally Invasive Glaucoma Surgery: A Health Technology Assessment

Last Updated: March 14, 2019
Result type: Reports
Product Line: Optimal Use

Glaucoma is a leading cause of blindness. A range of surgical interventions exist for treating glaucoma, including a group of procedures commonly called micro-invasive or minimally invasive glaucoma surgery (MIGS). It has been noted that, across Canada, there is a growing demand for MIGS, as well as a rise in the use of MIGS procedures. At the s...

  • Project Number: OP0532-000

Tisagenlecleucel (Kymriah) for Pediatric Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma

Last Updated: January 15, 2019
Result type: Reports
Product Line: Optimal Use

Tisagenlecleucel is a chimeric antigen receptor (CAR) T-cell therapy for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma and children and young adults with relapsed or refractory acute lymphoblastic leukemia. CADTH undertook a review of manufacturer-submitted materials and published literature to assess the cli...

  • Project Number: OP0538-000 / CT0001